Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pediatric Hematology/Oncology
•
Medical Oncology
•
Hematology
Would you consider bone marrow transplant in a pediatric patient with recurrent HLH with no identified exogenous trigger or HLH-associated mutation?
Related Questions
How would you approach adjusting nivo+AVD therapy for advanced Hodgkin lymphoma if a patient develops treatment limited immunotherapy toxicity?
What screening tools or signs do you use to predict if a cancer patient is near end-of-life?
What is the optimal timing for PET/CT to assess disease and treatment response with nivo + AVD?
Is there any indication for IVIG in immunocompromised patients with only decreased IgM and/or IgA levels?
What are your top takeaways in Classical Hematology from ASH 2024?
How would you counsel patients with personal or family histories of autoimmune disease on immune checkpoint inhibitor therapy for Hodgkin lymphoma?
What are your top takeaways from ISTH 2025?
How do different inflammatory markers like CRP and ferritin contribute differently, if at all, to the monitoring of CART neurotoxicity?
Given the data from SWOG 1826 suggesting that Nivo-AVD is likely the preferred regimen for advanced Hodgkin lymphoma patients, are there scenarios where alternative regimens may still be preferred?
How do you manage patients desiring home hospice but with severe thrombocytopenia and/or anemia due to advanced malignancy?
